Navigation Links
Generex Provides Preliminary Results of Generex Oral-lyn™ Clinical Trials in Patients with Type 1 Diabetes and Patients with Impaired Glucose Tolerance
Date:7/8/2011

WORCESTER, Mass. and TORONTO, July 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTC Bulletin Board: GNBT) (www.generex.com) today announced preliminary clinical results of two major trials using the Generex Oral-lyn™ formulation that will be used for registration and marketing.  Unlike prior reported results from studies using older versions of the formulation, the combined data from the now completed 084 Trial in Type 1 patients and the Prevoral Trial in patients with Impaired Glucose Tolerance provide key insights into both the short-term pharmacokinetic and glucodynamic effectiveness of Generex Oral-lyn™ in reducing post-prandial increases in blood sugar as well as the long-term (one year) safety and positive effect on metabolic control using the registration formulation of Generex Oral-lyn™.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

In the 084 Trial the final patient completed last visit in June providing 463 type 1 diabetes patients completing the study.  The Prevoral trial had 31 patients with obesity and Impaired Glucose Tolerance (a pre-diabetes syndrome) completing the study.

Generex Oral-lyn™ was designed as a prandial (meal-time) insulin to replace the failing rapid secretion of insulin, which a healthy person's insulin secreting cells in the pancreas normally produce in response to eating a meal.  While equally important in both type 1 and type 2 diabetes patients, this rapid release of insulin (first phase release) is one of the first abnormalities to occur in type 2 patients and in those individuals with pre-diabetes.  The ability to reduce post meal hyperglycemia by replacing this first phase insulin release is key to providing glucose control in all patients
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Generex Announces Appointment of CEO for Post-Spinout Antigen Express
2. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
3. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
4. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
5. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
6. Generex Launches New Corporate Website
7. Generex Unveils Strategic Development Plan
8. Generex Plans Rights Offering Upon Approval of Reverse Stock Split and Listing on a National Stock Exchange
9. Generex Provides Further Information for March 30 Press Conference & Investor Call to Discuss Managements Strategic Development Plan for Future Growth
10. Generex Schedules Press Conference & Investor Call for March 30th to Discuss Managements Strategic Development Plan for Future Growth
11. Generex Announces New Treatment IND Site for the USFDA Expanded Access Treatment IND Program for Generex Oral-lyn™ in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 Par Pharmaceutical Companies, Inc. ... on Friday, August 7, 2015 at 9:00 a.m. EDT ... quarter ended June 30, 2015.  Par is privately held ... public in its filings with the Securities and Exchange ... its website by following the instructions at http://www.parpharm.com/financialinfo ...
(Date:8/3/2015)... 3, 2015 Ortho Clinical Diagnostics (OCD) today ... Chief Corporate Brand and Communications Officer, effective immediately. As ... Bouryal will lead the company,s worldwide corporate brand and ... to an independent company by adding sites in countries ... Chief Executive Officer Dr. Martin Madaus . ...
(Date:8/3/2015)... 2015 According to a ... "Global Market Study on Physiotherapy Equipment - ... by 2022", the global physiotherapy equipment market is estimated to ... 2015 and is expected to grow at a ... account for US$23.7 Bn by 2022. View ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... TROY, Mich., Oct. 25, 2011 CareTech Solutions, an ... for over 180 U.S. hospitals announced today that the ... information officer, Detroit Medical Center (DMC), Vanguard Health System ... the 2011 College of Health Information Management Executives (CHIME) ...
... Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the ... today the contractual agreements for S1P1 lead compounds, AMG ... a sealed bid sale.   AMG-369, AMG-277 ... as part of License Agreement between Amgen and Epix ...
Cached Medicine Technology:Detroit Medical Center Shares Smart Room Case Study at CHIME 2011 Fall CIO Forum 2Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... They know ... Providence St. Vincent Medical Center offers some of the best care in the ... neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the country. ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles ... need. Most people know that general health emergencies, such as broken arms or a ... people know where to turn to during a dental emergency. This is important, because ...
(Date:8/3/2015)... , ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: ... is scheduled to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 ... webcast and subsequent archived replay of the Company’s presentation may be accessed via the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article ... Stem Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" ... to the report, the new study showed that harvesting stem cell-rich bone marrow from ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... research suggests that the patients who undergo surgery to ... later developing pancreatic cancer. The investigators base their findings ... operation known as gastrectomy to remove their ulcers.// ... the stomach or a portion of the small intestine, ...
... has sex and any subsequent risk of birth defects such ... of sex might increase the risk of birth defects in ... and gynecology at Baylor College of Medicine in Houston told ... known causes of birth defects in lower animals. ...
... The government approved a long-awaited treatment for lymphoma - ... radiation directly to cancer cells. Idec Pharmaceuticals' Zevalin becomes ... US. // ,It's a new approach, adding ... CD20 found on lymphoma cells. The antibodies attach to ...
... group have developed an efficient method of identifying strains ... diseases such as meningococcal disease. The Cooperative ... Technology (QUT) has taken advantage of two new technologies// ... recently - DNA chip technology and comparative gene sequence ...
... which could make gene therapy powerful. The advance which is ... the modified genes to slip right into the cell nucleus.A ... an entire human.// ,This means that the DNA molecule ... smuggle or slip their modified DNA strands into the cells ...
... to a new study, filtering out the antibodies that can ... live donor transplants. Many patients need a kidney transplant but ... Body organs, from dead bodies, are in short supply, and ... must be of a compatible blood group. ,But ...
Cached Medicine News:Health News:Ulcer Surgery connected to danger of Pancreatic Cancer 2Health News:Identifying bacteria made amiable 2
... Plus Dodeca cell accommodates up to 12 ... first-dimension runs in the PROTEAN IEF system, ... format. The PROTEAN Plus Dodeca cell's cooling ... electrodes, allow consistent, high-resolution results. The handcasting ...
... The PROTEAN Plus Dodeca cell accommodates up ... capacity of first-dimension runs in the PROTEAN ... a convenient format. The PROTEAN Plus Dodeca ... its plate electrodes, allow consistent, high-resolution results. ...
... gels run in the specially designed E-Base™ ... power supply in one device. The daughter ... and to other daughter E-Base™ platforms for ... E-Gel® 96 or E-Gel® 48 gels. Note: ...
... E-Gel® 48 gels run in the ... combine the base and power supply ... E-Base™ power supply contains an electrical ... to an electrical outlet and is ...
Medicine Products: